a recommended determination on remedy and bond. The final ID found that no violation of section 337 has occurred in the importation into the United States, the sale for importation, or the sale within the United States after importation, of certain video processing devices and components thereof by reason of infringement of claims 29, 30, and 32 of the '673 patent; claims 1 and 2 of the '297 patent; claims 1, 2, 5, 6, and 7 of the '588 patent; and claims 11 and 17 of the '553 patent.

The ID found that the accused products do not infringe the asserted claims of any of the asserted patents. The ID also found that the domestic industry requirement (both technical and economic prongs) has not been satisfied with respect to the '673, '297, '588, and '553 patents.

The ID further found that it has not been shown by clear and convincing evidence that the asserted claims of the '673, '297, '588, and '553 patents are invalid.

On June 10, 2024, complainant DivX filed ''Complainant DivX, LLC's Petition for Review of the Initial Determination.'' Likewise, on June 10, 2024, respondent Amazon filed ''Contingent Petition for Review of May 29, 2024, Initial Determination by Respondent Amazon.com, Inc.'' Subsequently, on June 18, 2024, DivX filed ''Complainant DivX, LLC's Response to Contingent Petition for Review of May 29, 2024, Initial Determination by Respondent Amazon.com, Inc.,'' and Amazon filed ''Response to Complainant's Petition for Review of May 29, 2024 Initial Determination by Respondent Amazon.com, Inc.''

Having examined the record in this investigation, including the final ID, the petitions for review, and the responses thereto, the Commission has determined to review in part the ID and, on review, to affirm the final ID with the following modifications. Specifically, the Commission has determined to review section IV of the final ID, JURISDICTION (*see* ID at 15–16). On review and as discussed more fully in the Commission Opinions recently issued in Inv. Nos. 337–TA–1355 and 337–TA–1362, the Commission clarifies that the terms ''subject matter jurisdiction,'' ''personal jurisdiction,'' and ''*in rem* jurisdiction'' are not necessarily applicable to the Commission's investigative authority under section 337. *See Certain Liquid Transfer Devices with an Integral Vial Adapter,* Inv. No. 337–TA–1362, Comm. Op. at 9 (Jul. 26, 2024); *Certain Compact Wallets and Components Thereof,* Inv. No. 337–TA–1355, Comm. Op. at 11–12 (Aug. 13, 2024). The Commission is ''a creature of statute.'' *Kyocera* v. *Int'l Trade Comm'n,* 545 F.3d 1340, 1355 (Fed. Cir. 2008). Accordingly, pursuant to its enabling statute, the Commission has statutory authority to investigate an alleged violation of section 337 where a complaint alleges that the named respondents have imported, sold for importation, or sold after importation articles that, *inter alia,* infringe a valid and enforceable U.S. patent. 19 U.S.C. 1337(a)(1)(B). The Commission likewise has authority over accused products based on their alleged importation, sale for importation, or sale after importation into the United States.

Second, the Commission has determined to review the economic prong of domestic industry requirement in its entirety, and on review, affirm a finding of no domestic industry under modified reasoning. Specifically, on review, the Commission finds that DivX has failed to establish a domestic industry based upon the finding that DivX failed to satisfy the technical prong of the domestic industry requirement for the Asserted Patents (ID at 39, 47, 69). When a section 337 investigation is based on allegations of patent infringement, the complainant must show that ''an industry in the United States, relating to the articles protected by the patent . . . exists or is in the process of being established.'' 19 U.S.C. 1337(a)(2). Because there are no articles protected by the Asserted Patents, DivX failed to satisfy the domestic industry requirement.

The Commission has also determined to review sections VI.D (validity with respect to the '673 patent, ID at 47–53); VII.D (validity with respect to the '297 patent, ID at 69–84); VIII.D (validity with respect to the '553 patent, ID at 101–104); IX.D (validity with respect to the '588 patent, ID at 116–121), and X (Amazon's defenses, ID at 121–127), and on review, the Commission takes no position. *See Beloit Corp.* v. *Valmet Oy,* 742 F.2d 1421, 1423 (Fed. Cir. 1984).

Finally, the Commission notes a typographical error in the third sentence on page 1 of the final ID. The Commission interprets that sentence to mean:

> The complaint alleges a violation of section 337 in the importation into the United States, the sale for importation, or the sale within the United States after importation of certain video processing devices and components thereof by reason of the infringement of certain claims of U.S. Patent Nos. 8,832,297 (the '' '297 patent''); 7,295,673 (the '' '673 patent''); 10,225,588 (the '' '588 patent''); 11,102,553 (the '' '553 patent''); and 11,050,808 (''the '808 patent'').

The Commission has determined not to review the remainder of the ID, including the ID's finding of no violation of section 337 in this investigation.

The investigation is hereby terminated.

The Commission vote for this determination took place on August 30, 2024.

The authority for the Commission's determination is contained in section 337 of the Tariff Act of 1930, as amended, 19 U.S.C. 1337, and in part 210 of the Commission's Rules of Practice and Procedure, 19 CFR part 210.

By order of the Commission.

Issued: August 30, 2024.

Sharon Bellamy,

Supervisory Hearings and Information Officer.

[FR Doc. 2024–20067 Filed 9–5–24; 8:45 am]

BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1426]

Importer of Controlled Substances Application: Bright Green Corporation

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Bright Green Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 7, 2024. Such persons may also file a written request for a hearing on the application on or before October 7, 2024.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking

Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on July 30, 2024, Bright Green Corporation, 1033 George Hanosh Boulevard, Grants, New Mexico 87020, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract	7350	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I

The company plans to import tissue culture that will be used to begin the propagation of their bulk cannabis manufacturing operation. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Marsha L. Ikner,

Acting Deputy Assistant Administrator.

[FR Doc. 2024–20083 Filed 9–5–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1425]

Importer of Controlled Substances Application: Biopharmaceutical Research Company

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.

SUMMARY: Biopharmaceutical Research Company has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to **SUPPLEMENTARY INFORMATION** listed below for further drug information.

DATES: Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before October 7, 2024. Such persons may also file a written request for a hearing on the application on or before October 7, 2024.

ADDRESSES: The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to *https://www.regulations.gov* and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on *https://www.regulations.gov.* If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION: In accordance with 21 CFR 1301.34(a), this is notice that on July 17, 2024, Biopharmaceutical Research Company, 11045 Commercial Parkway, Castroville, California 95012–3209, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

Controlled substance	Drug code	Schedule
Marihuana Extract	7350	I
Marihuana	7360	I
Tetrahydrocannabinols	7370	I

The company plans to import Marihuana Extract (7350), Marihuana (7360) and Tetrahydrocannabinols (7370) as flowering plants and cannabis derivatives to support analytical chemistry analyses, research and the manufacturing of dosage forms for pre-clinical and clinical trials. No other activities for these drug codes are authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Marsha L. Ikner,

Acting Deputy Assistant Administrator.

[FR Doc. 2024–20085 Filed 9–5–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

[Docket No. DEA–1429]

Importer of Controlled Substances Application: Cambridge Isotope Laboratories, Inc.

AGENCY: Drug Enforcement Administration, Justice.

ACTION: Notice of application.